Be­hind Fri­day's $161M IPO: A star sci­en­tist, GPCR drug dis­cov­ery and a plan to chal­lenge phar­ma in di­a­betes

What does it take to pull off a $161 mil­lion biotech IPO these days?

In Struc­ture Ther­a­peu­tics’ case, it means hav­ing a star sci­en­tist co-founder paired with the com­pu­ta­tion­al drug dis­cov­ery com­pa­ny Schrödinger, $198 mil­lion in pri­vate fund­ing from blue-chip in­vestors, al­most six years of re­search work on G pro­tein-cou­pled re­cep­tors and a slate of oral, small-mol­e­cule drugs, with an eye on the huge and grow­ing di­a­betes and weight-loss mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER